jak in 15

JAK-IN-15 is a JAK inhibitor. WO2016119700A1 (Compound 15).

1. Linderalactone showed significant inhibitory effects on superoxide anion generation by human neutrophils in response to fMLP/CB, values of IC5 is 8.48 μg/mL.

JAK-IN-30 (compound 31) is a water-soluble inhibitor of Janus kinases (JAKs), demonstrating inhibitory potency with half-maximal inhibitory concentration (IC50) values of 2 nM for JAK2, 15 nM for JAK1, 18 nM for JAK3, and 2 nM for TYK2. The compound has been identified as having research potential for the treatment of dry eye disease (DED) [1].

JAK-IN-24, a JAK inhibitor, exhibits IC50 values of 0.534 nM and 24 nM in the presence of 4 μM and 1 mM ATP, respectively. Additionally, it effectively inhibits STAT5 phosphorylation induced by PBMC IL-15 with an IC50 of 86.171 nM.

JAK-IN-23 is an orally active dual JAK/STAT and NF-κB inhibitor that inhibits J AK1 (IC50: 8.9 nM), J AK2 (IC50: 15 nM), and J AK3 (IC50: 46.2 nM). JAK-IN-23 exhibits strong anti-inflammatory effects and can reduce the release of various pro-inflammatory factors.JAK-IN-23 can be used to study inflammatory bowel disease (IBD).